Increasing Funding for Cancer Research is Offering an Opportunity for North American Cancer Monoclonal Antibodies Market

North American cancer monoclonal antibodies market is estimated to grow at a CAGR of 9.6% during the forecast period. Significant availability of funding for cancer research is providing scope for market growth. For instance, the FY 2020 Department of Health and Human Services Appropriations Act and the 21st Century Cures Act distributed $6.4 billion to National Cancer Institute (NCI), a $297 million net growth over the FY 2019. This funding supports NCI to provide grants to investigators' research to perform clinical trials. As a result, several novel monoclonal antibodies for cancer treatment are in clinical trials. Additionally, biotechnology companies are partnering to develop novel monoclonal antibodies. 

Browse the full report description of "North American cancer monoclonal Antibodies Market Size, Share & Trends Analysis Report, By Type (Naked, Conjugated, and Others), By Application (Breast Cancer, Liver Cancer, Blood Cancer, Brain Cancer, Colorectal Cancer, and Others) and Forecast, 2020-2026" at https://www.omrglobal.com/industry-reports/north-american-cancer-monoclonal-antibodies-market

For instance, in June 2019, OSE Immunotherapeutics SA and Boehringer Ingelheim declared that they have started a first-in-human Phase 1 clinical trial assessing BI 765063, earlier OSE-172. It is a first-in-class monoclonal antibody antagonist of SIRP?, which is being studied in patients suffering from advanced solid tumors. In April 2018, both the companies declared global collaboration and license agreement for joint development of OSE-172, a SIRP-alpha antagonist targeting myeloid lineage cells. The launch of novel monoclonal antibodies will further increase the availability of potential therapies, which in turn, will offer an opportunity for market growth.  

Scope of the North American Cancer Monoclonal Antibodies Market

Market Coverage

• Market number available for 2019-2026
• Base year- 2019
• Forecast period- 2020-2026
• Segment Covered- By Type and Application
• Countries Covered- US and Canada
• Competitive Landscape- Amgen Inc., Eli Lilly & Co., Pfizer Inc., Merck & Co., Inc., and F. Hoffman La-Roche AG

Recent Strategic Initiatives in the North American Cancer Monoclonal Antibodies Market

• In December 2019, Mylan N.V. and Biocon Ltd. declared the US FDA launch of Ogivri (trastuzumab-dkst). It is biosimilar to Herceptin (trastuzumab). It was the first biosimilar trastuzumab approved by the US FDA for all indications which includes treatment of HER2-overexpressing metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) and breast cancer. 
• In June 2018, Pfizer Inc. announced the approval of ZIRABEV (bevacizumab-bvzr) in the US. It is a biosimilar to Avastin (bevacizumab) which is indicated to treat five kinds of cancer, including locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (NSCLC), metastatic colorectal cancer, unresectable, metastatic renal cell carcinoma (RCC), recurrent glioblastoma; and persistent, recurrent or metastatic cervical cancer. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment dominates the market in the base year?
• Which segment will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from the pre-COVID forecast

o Most affected segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

North American Cancer Monoclonal Antibodies Market-Segmentation

By Type

• Naked 
• Conjugated
• Others (Bispecific)

By Application

• Breast Cancer
• Liver Cancer
• Blood Cancer
• Brain Cancer
• Colorectal Cancer
• Others

North American Cancer Monoclonal Antibodies Market– Segment by Country

• US
• Canada

To learn more about this report request a free sample copy @  https://www.omrglobal.com/request-sample/north-american-cancer-monoclonal-antibodies-market